Silencing of integrin-linked kinase suppresses in vivo tumorigenesis of human ovarian carcinoma cells

Molecular Medicine Reports

Volumn 7, Issue 3, 2013, Pages 1050-1054

  Li, Qi ^a   Li, Chen ^b   Zhang, Yun Yan ^a   Chen, Wei ^a   Lv, Jun Li ^a   Sun, Jing ^a   You, Qing Shan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HEILONGJIANG PROVINCIAL HOSPITAL   (China)

Author keywords

Gene silence; Integrin linked kinase; Nude mice xenografts; Ovarian cancer; Tumorigenesis

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; INTEGRIN LINKED KINASE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; ARTICLE; BODY WEIGHT; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CARCINOGENESIS; CARCINOMA; CELL LINE, TUMOR; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84873203417     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1285     Document Type: Article

References (21)

1. Notani P: Global variation in cancer incidence and mortality. Curr Sci 81:465-475, 2001.
2. Holschneider CH and Berek JS: Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19:3-10, 2000. (Pubitemid 30439309)
3. Cannistra SA, Ottensmeier C, Niloff J, Orta B and Di Carlo J: Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol Oncol 58:216-225, 1995.
4. Cruet-Hennequart S, Maubant S, Luis J, Gauduchon P, Staedel C and Dedhar S: alpha (v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 22:1688-1702, 2003. (Pubitemid 36408184)
5. Ruseva Z, Geiger PX, Hutzler P, Kotzsch M, Luber B, Schmitt M, Gross E and Reuning U: Tumor suppressor KAI1 affects integrin alphavbeta3-mediated ovarian cancer cell adhesion, motility, and proliferation. Exp Cell Res 315:1759-1771, 2009.
6. Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt MR, Montag AG, Kistner E, Yamada SD, Mitra AK and Lengyel E: {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol 175:2184-2196, 2009.
7. Mulrooney J, Foley K, Vineberg S, Barreuther M and Grabel L: Phosphorylation of the beta1 integrin cytoplasmic domain: toward an understanding of function and mechanism. Exp Cell Res 258:332-341, 2000. (Pubitemid 30483511)
8. Dedhar S, Williams B and Hannigan G: Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Trends Cell Biol 9:319-323, 1999. (Pubitemid 29339148)
9. McDonald PC, Fielding AB and Dedhar S: Integrin-linked kinase - essential roles in physiology and cancer biology. J Cell Sci 121:3121-3132, 2008.
10. Ahmed N, Riley C, Oliva K, Stutt E, Rice GE and Quinn MA: Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. J Pathol 201:229-237, 2003. (Pubitemid 37258934)
11. Gao J, Zhu J, Li HY, Pan XY, Jiang R and Chen JX: Small interfering RNA targeting integrin-linked kinase inhibited the growth and induced apoptosis in human bladder cancer cells. Int J Biochem Cell Biol 43:1294-1304, 2011.
12. Pontier SM, Huck L, White DE, Rayment J, Sanguin-Gendreau V, Hennessy B, Zuo D, St-Arnaud R, Mills GB, Dedhar S, et al: Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. Oncogene 29:3374-3385, 2010.
13. Chan J, Ko FC, Yeung YS, Ng IO and Yam JW: Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. PLoS One 6:e16984, 2011.
14. Liu Q, Xiao L, Yuan D, Shi X and Li P: Silencing of the integrin-linked kinase gene induces the apoptosis in ovarian carcinoma. J Recept Signal Transduct Res 32:120-127, 2012.
15. Hannigan G, Troussard AA and Dedhar S: Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 5:51-63, 2005. (Pubitemid 40052325)
16. Yang Y, Fukui K, Koike T and Zheng X: Induction of autophagy in neurite degeneration of mouse superior cervical ganglion neurons. Eur J Neurosci 26:2979-2988, 2007. (Pubitemid 350115519)
17. McDonald PC and Dedhar S: The role of integrin-linked kinase in cancer development and progression. In: Cell-Extracellular Matrix Interactions in Cancer. Zent R and Pozzi A (eds). Springer, New York, pp245-273, 2010.
18. Monteith DK, Geary RS, Leeds JM, Johnston J, Monia BP and Levin AA: Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol Sci 46:365-375, 1998. (Pubitemid 29069621)
19. Radeva G, Petrocelli T, Behrend E, Leung-Hagesteijn C, Filmus J, Slingerland J and Dedhar S: Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J Biol Chem 272:13937-13944, 1997. (Pubitemid 27224838)
20. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J and Dedhar S: Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 97:3207-3212, 2000. (Pubitemid 30183280)
21. Rayburn ER and Zhang R: Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today 13:513-521, 2008.